Family Legacy Inc. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 3,715 shares of the company’s stock, valued at approximately $359,000.
Other large investors also recently made changes to their positions in the company. Ffcm LLC raised its holdings in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares in the last quarter. Bristlecone Advisors LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth approximately $113,000. Hershey Trust Co. purchased a new stake in shares of AbbVie during the 3rd quarter worth approximately $139,000. Harvest Fund Management Co. Ltd raised its holdings in shares of AbbVie by 1,172.6% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 2,227 shares of the company’s stock worth $161,000 after acquiring an additional 2,052 shares in the last quarter. Finally, Atlantic Trust LLC raised its holdings in shares of AbbVie by 208.4% during the 2nd quarter. Atlantic Trust LLC now owns 2,467 shares of the company’s stock worth $179,000 after acquiring an additional 1,667 shares in the last quarter. Institutional investors own 70.54% of the company’s stock.
NYSE:ABBV opened at $94.65 on Friday. AbbVie Inc. has a fifty-two week low of $63.12 and a fifty-two week high of $125.86. The firm has a market cap of $150,301.66, a P/E ratio of 16.90, a P/E/G ratio of 0.88 and a beta of 1.52. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28.
AbbVie announced that its board has authorized a share repurchase program on Thursday, February 15th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be issued a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a yield of 4.06%. The ex-dividend date of this dividend is Thursday, April 12th. This is a positive change from AbbVie’s previous quarterly dividend of $0.71. AbbVie’s dividend payout ratio is presently 50.71%.
In other AbbVie news, CFO William J. Chase sold 70,928 shares of the stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $117.18, for a total value of $8,311,343.04. Following the sale, the chief financial officer now owns 203,391 shares in the company, valued at $23,833,357.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 8,280 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $117.88, for a total value of $976,046.40. Following the completion of the sale, the chairman now owns 321,292 shares in the company, valued at approximately $37,873,900.96. The disclosure for this sale can be found here. Insiders have sold a total of 211,197 shares of company stock worth $24,585,575 in the last 90 days. 0.07% of the stock is currently owned by insiders.
Several brokerages have recently issued reports on ABBV. Piper Jaffray upped their price objective on AbbVie from $115.00 to $130.00 and gave the stock an “outperform” rating in a report on Friday, January 26th. SunTrust Banks upped their price objective on AbbVie to $157.00 and gave the stock an “average” rating in a report on Monday, January 29th. Leerink Swann cut AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price objective on the stock. in a report on Monday, January 29th. BMO Capital Markets cut AbbVie from a “market perform” rating to an “underperform” rating and decreased their price objective for the stock from $125.86 to $84.00 in a report on Monday, January 29th. They noted that the move was a valuation call. Finally, Evercore ISI reaffirmed a “buy” rating and set a $144.00 price objective on shares of AbbVie in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $116.68.
ILLEGAL ACTIVITY WARNING: This piece was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/04/01/family-legacy-inc-takes-position-in-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.